Developer docs
API playgroundTry for free, no card

Search company profiles

ASP Isotopes

Full company profile

uuid00002is

Namestring
ASP Isotopes
Legal namestring
ASP Isotopes Inc.
Websiteurl
aspisotopes.com
Company typeenum
Public
Founded yearint
2022
Descriptiontext

ASP Isotopes Inc. (NASDAQ: ASPI; JSE-listed) is a vertically integrated advanced materials company that develops and operates proprietary isotope enrichment technology across three end markets: medical/healthcare (radiopharmaceuticals and nuclear medicine), semiconductors (Silicon-28, Ytterbium-176, Barium-137 for quantum computing applications), and nuclear energy (High Assay Low Enriched Uranium via its Quantum Leap Energy subsidiary). The company deploys two proprietary core technologies — the Aerodynamic Separation Process (ASP), a gaseous diffusion method using stationary wall centrifuges and proprietary flow directors, and Quantum Enrichment (QE), a laser-based isotope separation platform using precisely tuned lasers and quantum mechanical selectivity. Founded in 2021/2022 and IPO'd on NASDAQ in November 2022, the company operates isotope enrichment facilities in Pretoria, South Africa, has expanded into radiopharmacy distribution through acquired PET Labs operations in Florida and South Carolina, and has strategic nuclear fuel partnerships with Necsa (Pelindaba), TerraPower (Natrium reactor), Fermi America (Amarillo, TX), and unnamed European and U.S. energy majors.

Revenue is generated primarily from B2B enterprise supply contracts for enriched isotopes and from helium and LNG production through the recently acquired Renergen/Virginia Gas Project in South Africa's Free State (Phase 1 producing 58,000 cubic ft/day of liquid helium and 2,500 GJ/day of LNG, with first take-or-pay contract at prices exceeding $600/MCF). Pricing is contract-based rather than published list pricing, with revenue model types spanning one-time license/sales for isotope shipments and subscription/take-or-pay recurring structures for helium and HALEU nuclear fuel supply. Commercial-scale shipments of Silicon-28, Carbon-14, and Ytterbium-176 are scheduled for Q3 2026, with HALEU deliveries targeted from 2028 through 2036. The company reported $5.7 million in FY2025 product revenue and $23.8 million in Q4 2025 total revenue (a 480% YoY increase), carried a $175.1 million FY2025 net loss against $333 million in cash at year-end 2025, and has a long-term financial target of greater than $300 million EBITDA by 2031.

Short descriptiontext

ASP Isotopes Inc. (NASDAQ: ASPI) enriches isotopes through proprietary Aerodynamic Separation Process and Quantum Enrichment laser technologies, supplying Silicon-28, Ytterbium-176, Carbon-14, and HALEU nuclear fuel to medical radiopharmacy, quantum-computing semiconductor, and advanced nuclear reactor customers in the U.S., South Africa, and U.K.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stable isotope enrichment, medical isotope production, HALEU nuclear fuel, aerodynamic separation process, quantum enrichment technology
Industry4 codes
PRIMARYEUAKACAH
HALEU Production & Supply Chain (Feedstock, Enrichment, Downblending)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Fuel Cycle (Mining, Conversion, Enrichment & Fuel Fabrication)
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUACADAK
Nuclear Fuel Cycle for Power Generation (Uranium, Conversion, Enrichment, Fuel Fabrication)
SECONDARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Industrial Gas Manufacturing32512
Product category
Stable Isotope Enrichment
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Isotope Sales - Medical/Radiopharmaceuticals
TypeOne Time License
Description

Revenue from enriched medical isotopes including Carbon-14 and ytterbium-based products for cancer therapy and diagnostic imaging. The company acquired radiopharmacies in Florida and South Carolina to expand this segment. Q4 2025 showed 480% revenue growth driven by radiopharmaceutical operations.

businessday.co.za
2Isotope Sales - Semiconductors
TypeOne Time License
Description

Revenue from enriched Silicon-28 for quantum computing and next-generation semiconductor applications. Three commercial contracts with U.S.-based customers, with initial commercial shipments expected in Q3 2026. The largest silicon-28 supply contract to date was signed in October 2025.

stocktitan.net
3Helium and LNG Production
TypeSubscription Recurring
Description

Revenue from Virginia Gas Project in South Africa's Free State Province producing liquid helium (58,000 cubic ft/day at Phase 1) and LNG (2,500 GJ/day). First take-or-pay contract secured with Asian industrial gases company for approximately 15% of Phase 1 nameplate capacity at price exceeding $600/MCF.

stocktitan.net
4HALEU Nuclear Fuel
TypeSubscription Recurring
Description

High Assay Low Enriched Uranium production for advanced reactors including small modular reactors. Partnerships with TerraPower, European nuclear technology companies, and U.S. energy companies for supply. Deliveries projected to begin in 2028 and scale through 2036.

etftrends.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Quantum Leap Energy
Description

Nuclear fuel subsidiary focused on advanced nuclear fuel technologies including HALEU enrichment and laser-based uranium enrichment for advanced reactors and fusion systems.

aspisotopes.com
+1 more record
Core offering1 text field

ASP Isotopes manufactures and supplies enriched stable isotopes for medical, semiconductor, and nuclear energy applications, including Silicon-28, Ytterbium-176, Carbon-14, and Barium-137. The company also produces HALEU (High-Assay Low-Enriched Uranium) nuclear fuel through its Quantum Leap Energy subsidiary and helium and LNG (liquefied natural gas) from the Virginia Gas Project.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 480% year-over-year revenue growth in Q4 2025 ($23.8M vs $4.1M)
+4 more records
Product overview1 text field

ASP Isotopes Inc. is an advanced materials company operating as a platform-plus-technologies architecture focused on isotope enrichment. The company utilizes two proprietary core enrichment technologies: Aerodynamic Separation Process (ASP) using stationary wall centrifuges, and Quantum Enrichment (QE) using laser-based quantum mechanical principles. The technology platform serves three end markets: Medical (radiopharmaceuticals and nuclear medicine through PET Labs operations), Semiconductors (Silicon-28, Ytterbium-176, Carbon-14, Barium-137 for quantum computing and advanced electronics), and Nuclear Energy (through subsidiary Quantum Leap Energy focused on HALEU production). The Renergen Virginia Gas Project acquisition adds helium and LNG production capabilities. The portfolio also includes strategic partnerships for uranium enrichment at Necsa's Pelindaba site in South Africa and joint ventures with Fermi America in Texas.

Product and service7 records
1Silicon-28
CategoryEnriched Stable Isotopes
2Ytterbium-176
CategoryMedical Isotopes
3Carbon-14
CategoryMedical Isotopes
4Barium-137
CategoryEnriched Stable Isotopes
5HALEU (High-Assay Low-Enriched Uranium)
CategoryNuclear Fuel
6Helium
CategoryIndustrial Gases
7Liquefied Natural Gas (LNG)
CategoryIndustrial Gases
Scale indicator17 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-25
Description

Proposed merger where ASP Isotopes' subsidiary Noble Africa LLC merges with ENDRA subsidiary to form Noble Africa Inc., a Nasdaq-listed company focused on helium and natural gas development through Renergen's Virginia Gas Project in South Africa. Transaction includes concurrent $50 million private placement financing with ASP Isotopes contributing $20 million as lead investor. ASP Isotopes retains approximately 89% ownership post-merger. Expected to close Q3/Q4 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Tetra4, a subsidiary of Renergen and developer of the Virginia Gas Project, secured its first take-or-pay contract for liquid helium supply to an Asian industrial gases company. The five-year agreement covers approximately 15% of Phase 1 nameplate capacity at a price exceeding $600/MCF, with commercial production expected Q3 2026. Phase 2 is approximately 13 times larger than Phase 1.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-14
Description

ASP Isotopes completed acquisition of Renergen Limited for $129.4 million in January 2026. Renergen operates the Virginia Gas Project in South Africa's Free State Province - a helium and LNG production asset. Phase 1 drilling completed April 2026, four months ahead of schedule. Provides critical helium supply for semiconductor and medical imaging industries.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-11
Description

Quantum Leap Energy entered non-binding MOU with European nuclear technology company for HALEU supply collaboration. European partner provides uranium feedstocks to QLE's planned conversion and enrichment facilities. Potential deliveries beginning 2028 and scaling through 2036. MOU extends through December 31, 2030.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Quantum Leap Energy partnership with University of Bristol to develop lithium laser enrichment research facility in the UK. Collaboration advances QLE's laser enrichment technology research and development capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-06
Description

Quantum Leap Energy signed non-binding MOU with major publicly traded US energy company to evaluate support for establishing advanced nuclear fuel production facilities in the US. Facilities would produce HALEU and LEU+ and provide uranium conversion and deconversion services. Addresses US domestic enrichment capacity needs ahead of 2028 Russian uranium import ban.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-20
Description

Quantum Leap Energy executed Pre-Implementation Services Contract with Necsa for siting, design, construction, and operation of a HALEU enrichment facility at Necsa's Pelindaba site. Collaboration leverages QLE's proprietary enrichment technology with Necsa's established nuclear infrastructure. Addresses growing global demand for HALEU fuel for small modular reactors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Joint venture with Fermi America (led by former Texas Governor Rick Perry) for development of HALEU enrichment research and commercial production facility in Amarillo, Texas. Partnership part of Project Matador - proposed 18+ million square foot AI campus powered by nuclear reactors. ASP Isotopes securing advanced reactor fuel supply for major US infrastructure project.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-08-29
Description

Quantum Leap Energy acquired controlling interest in SKBL (NASDAQ: SKBL) - holding 79.14% of voting power. QLE intends to use SKBL to pursue opportunities to acquire assets in the critical materials supply chain to help secure important feedstocks vital to US security.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-04
Description

Partnership with Isotopia for cancer therapy isotope development. ASP Isotopes announced $4 million isotope deal for novel antibody-isotope therapy development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-30
Description

Entered into term sheet with TerraPower (Bill Gates' nuclear company) for construction of HALEU production facility. TerraPower awarded key contracts to ASP Isotopes and Centrus Energy for HALEU fuel supply for its Natrium reactor project. ASP Isotopes positioned as critical supplier for next-generation nuclear fuel.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Centrus Energy is the only other company actively producing HALEU in the United States under contract to the Department of Energy and is a direct competitor for nuclear fuel supply to TerraPower and other advanced reactor developers — both Centrus and ASP Isotopes' Quantum Leap Energy subsidiary are pursuing HALEU/LEU+ production for the same advanced reactor customers.

TypeDirect peer
Description

SHINE Technologies is an emerging U.S. fusion-and-medical-isotope company producing medical isotopes (Mo-99, I-131, Lu-177) and investigating fusion-based enrichment, directly overlapping with ASP Isotopes' medical isotope and nuclear materials business across radiopharmaceutical supply.

TypeDirect peer
Description

Urenco is the world's leading commercial uranium enricher (LEU and stable isotopes) using centrifuge technology, competing head-to-head with ASP Isotopes' Aerodynamic Separation Process for nuclear fuel and stable isotope enrichment contracts globally.

TypeDirect peer
Description

NorthStar Medical is a U.S.-based medical isotope producer focused on Mo-99/Tc-99m and therapeutic radioisotopes, providing direct competition in the same radiopharmaceutical segment ASP Isotopes is targeting via its PET Labs radiopharmacy and Carbon-14/Ytterbium-176 programs.

TypeDirect peer
Description

Curium Pharma is one of the largest nuclear medicine and radiopharmaceutical manufacturers globally, directly comparable to ASP Isotopes' medical isotope portfolio and its radiopharmacy distribution through PET Labs acquisitions in Florida and South Carolina.

TypeBroad incumbent
Description

Cameco is a large, established nuclear fuel cycle incumbent spanning uranium mining, conversion, and fuel fabrication; while not directly competing in isotope enrichment, it sets the strategic reference point and competitive benchmark for ASP Isotopes' HALEU and uranium conversion services.

7Orano
TypeBroad incumbent
Description

Orano (formerly Areva) is a major French nuclear fuel cycle operator covering uranium mining, conversion, enrichment, and fuel fabrication; its global scale and existing enrichment infrastructure represent the broad incumbent benchmark for ASP Isotopes' emerging HALEU and conversion/deconversion ambitions.

TypeBroad incumbent
Description

Linde is one of the world's largest industrial gas producers, including helium production and supply, and operates radiopharmaceutical distribution; comparable to ASP Isotopes' Renergen Virginia Gas helium output (58,000 cu ft/day at Phase 1) and overlap with medical imaging gas customers.

TypeOthers
Description

TerraPower is Bill Gates' advanced reactor developer and a key demand-side partner/off-taker for ASP Isotopes' HALEU via the term sheet for the Natrium reactor; not a competitor, but a strategic customer and counterparty that directly determines the volume and timing of ASP's HALEU ramp.

TypeBroad incumbent
Description

BWX Technologies designs and manufactures nuclear components and TRISO fuel for advanced reactors and produces medical radioisotopes, positioning it as a broader nuclear industry incumbent relevant to both ASP Isotopes' HALEU fuel manufacturing plans and its medical isotope business.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ASP Isotopes

Stable Isotope Enrichmentaspisotopes.com

ASP Isotopes Inc. (NASDAQ: ASPI) enriches isotopes through proprietary Aerodynamic Separation Process and Quantum Enrichment laser technologies, supplying Silicon-28, Ytterbium-176, Carbon-14, and HALEU nuclear fuel to medical radiopharmacy, quantum-computing semiconductor, and advanced nuclear reactor customers in the U.S., South Africa, and U.K.

What ASP Isotopes does

ASP Isotopes Inc. (NASDAQ: ASPI; JSE-listed) is a vertically integrated advanced materials company that develops and operates proprietary isotope enrichment technology across three end markets: medical/healthcare (radiopharmaceuticals and nuclear medicine), semiconductors (Silicon-28, Ytterbium-176, Barium-137 for quantum computing applications), and nuclear energy (High Assay Low Enriched Uranium via its Quantum Leap Energy subsidiary). The company deploys two proprietary core technologies — the Aerodynamic Separation Process (ASP), a gaseous diffusion method using stationary wall centrifuges and proprietary flow directors, and Quantum Enrichment (QE), a laser-based isotope separation platform using precisely tuned lasers and quantum mechanical selectivity. Founded in 2021/2022 and IPO'd on NASDAQ in November 2022, the company operates isotope enrichment facilities in Pretoria, South Africa, has expanded into radiopharmacy distribution through acquired PET Labs operations in Florida and South Carolina, and has strategic nuclear fuel partnerships with Necsa (Pelindaba), TerraPower (Natrium reactor), Fermi America (Amarillo, TX), and unnamed European and U.S. energy majors.

Revenue is generated primarily from B2B enterprise supply contracts for enriched isotopes and from helium and LNG production through the recently acquired Renergen/Virginia Gas Project in South Africa's Free State (Phase 1 producing 58,000 cubic ft/day of liquid helium and 2,500 GJ/day of LNG, with first take-or-pay contract at prices exceeding $600/MCF). Pricing is contract-based rather than published list pricing, with revenue model types spanning one-time license/sales for isotope shipments and subscription/take-or-pay recurring structures for helium and HALEU nuclear fuel supply. Commercial-scale shipments of Silicon-28, Carbon-14, and Ytterbium-176 are scheduled for Q3 2026, with HALEU deliveries targeted from 2028 through 2036. The company reported $5.7 million in FY2025 product revenue and $23.8 million in Q4 2025 total revenue (a 480% YoY increase), carried a $175.1 million FY2025 net loss against $333 million in cash at year-end 2025, and has a long-term financial target of greater than $300 million EBITDA by 2031.

ASP Isotopes firmographics

Firmographics
Name
ASP Isotopes
Legal name
ASP Isotopes Inc.
Website
https://aspisotopes.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
101–250 employees
Short description
ASP Isotopes Inc. (NASDAQ: ASPI) enriches isotopes through proprietary Aerodynamic Separation Process and Quantum Enrichment laser technologies, supplying Silicon-28, Ytterbium-176, Carbon-14, and HALEU nuclear fuel to medical radiopharmacy, quantum-computing semiconductor, and advanced nuclear reactor customers in the U.S., South Africa, and U.K.
Ownership category
akta.pro rank

ASP Isotopes industry classification

Industry
Product category
Stable Isotope Enrichment
NAICS
Industrial Gas Manufacturing (32512)
akta.pro industry
PRIMARYEUAKACAH
HALEU Production & Supply Chain (Feedstock, Enrichment, Downblending)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Fuel Cycle (Mining, Conversion, Enrichment & Fuel Fabrication)
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUACADAK
Nuclear Fuel Cycle for Power Generation (Uranium, Conversion, Enrichment, Fuel Fabrication)
SECONDARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Stable isotope enrichment
  • Medical isotope production
  • HALEU nuclear fuel
  • Aerodynamic separation process
  • Quantum enrichment technology

Where ASP Isotopes is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Offices7 records

Markets served

ASP Isotopes business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Revenue model

  1. Isotope Sales - Medical/Radiopharmaceuticals: Revenue from enriched medical isotopes including Carbon-14 and ytterbium-based products for cancer therapy and diagnostic imaging. The company acquired radiopharmacies in Florida and South Carolina to expand this segment. Q4 2025 showed 480% revenue growth driven by radiopharmaceutical operations.
  2. Isotope Sales - Semiconductors: Revenue from enriched Silicon-28 for quantum computing and next-generation semiconductor applications. Three commercial contracts with U.S.-based customers, with initial commercial shipments expected in Q3 2026. The largest silicon-28 supply contract to date was signed in October 2025.
  3. Helium and LNG Production: Revenue from Virginia Gas Project in South Africa's Free State Province producing liquid helium (58,000 cubic ft/day at Phase 1) and LNG (2,500 GJ/day). First take-or-pay contract secured with Asian industrial gases company for approximately 15% of Phase 1 nameplate capacity at price exceeding $600/MCF.
  4. HALEU Nuclear Fuel: High Assay Low Enriched Uranium production for advanced reactors including small modular reactors. Partnerships with TerraPower, European nuclear technology companies, and U.S. energy companies for supply. Deliveries projected to begin in 2028 and scale through 2036.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

ASP Isotopes product offering

Product offering

Core offering

ASP Isotopes manufactures and supplies enriched stable isotopes for medical, semiconductor, and nuclear energy applications, including Silicon-28, Ytterbium-176, Carbon-14, and Barium-137. The company also produces HALEU (High-Assay Low-Enriched Uranium) nuclear fuel through its Quantum Leap Energy subsidiary and helium and LNG (liquefied natural gas) from the Virginia Gas Project.

Product overview

ASP Isotopes Inc. is an advanced materials company operating as a platform-plus-technologies architecture focused on isotope enrichment. The company utilizes two proprietary core enrichment technologies: Aerodynamic Separation Process (ASP) using stationary wall centrifuges, and Quantum Enrichment (QE) using laser-based quantum mechanical principles. The technology platform serves three end markets: Medical (radiopharmaceuticals and nuclear medicine through PET Labs operations), Semiconductors (Silicon-28, Ytterbium-176, Carbon-14, Barium-137 for quantum computing and advanced electronics), and Nuclear Energy (through subsidiary Quantum Leap Energy focused on HALEU production). The Renergen Virginia Gas Project acquisition adds helium and LNG production capabilities. The portfolio also includes strategic partnerships for uranium enrichment at Necsa's Pelindaba site in South Africa and joint ventures with Fermi America in Texas.

Differentiator

Problem solved

Functional benefit

Brands

  • Quantum Leap Energy: Nuclear fuel subsidiary focused on advanced nuclear fuel technologies including HALEU enrichment and laser-based uranium enrichment for advanced reactors and fusion systems.
  • Virginia Gas Project

Products and services

  • Silicon-28
  • Ytterbium-176
  • Carbon-14
  • Barium-137
  • HALEU (High-Assay Low-Enriched Uranium)
  • Helium
  • Liquefied Natural Gas (LNG)

Quantifiable outcome

  • 480% year-over-year revenue growth in Q4 2025 ($23.8M vs $4.1M)
  • +4 more outcomes

Companies that use ASP Isotopes

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles4 records

ASP Isotopes technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ASP Isotopes partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered flagship, core and minor.

  • ENDRA Life Sciences Inc.flagshipStrategic or Co-development Partner · 25 June 2026Proposed merger where ASP Isotopes' subsidiary Noble Africa LLC merges with ENDRA subsidiary to form Noble Africa Inc., a Nasdaq-listed company focused on helium and natural gas development through Renergen's Virginia Gas Project in South Africa. Transaction includes concurrent $50 million private placement financing with ASP Isotopes contributing $20 million as lead investor. ASP Isotopes retains approximately 89% ownership post-merger. Expected to close Q3/Q4 2026.
  • Tetra4 Proprietary LimitedcoreStrategic or Co-development Partner · 23 June 2026Tetra4, a subsidiary of Renergen and developer of the Virginia Gas Project, secured its first take-or-pay contract for liquid helium supply to an Asian industrial gases company. The five-year agreement covers approximately 15% of Phase 1 nameplate capacity at a price exceeding $600/MCF, with commercial production expected Q3 2026. Phase 2 is approximately 13 times larger than Phase 1.
  • Renergen LimitedflagshipStrategic or Co-development Partner · 14 May 2026ASP Isotopes completed acquisition of Renergen Limited for $129.4 million in January 2026. Renergen operates the Virginia Gas Project in South Africa's Free State Province - a helium and LNG production asset. Phase 1 drilling completed April 2026, four months ahead of schedule. Provides critical helium supply for semiconductor and medical imaging industries.
  • European Nuclear Technology Company (unnamed)coreStrategic or Co-development Partner · 11 May 2026Quantum Leap Energy entered non-binding MOU with European nuclear technology company for HALEU supply collaboration. European partner provides uranium feedstocks to QLE's planned conversion and enrichment facilities. Potential deliveries beginning 2028 and scaling through 2036. MOU extends through December 31, 2030.
  • University of BristolminorStrategic or Co-development Partner · 24 March 2026Quantum Leap Energy partnership with University of Bristol to develop lithium laser enrichment research facility in the UK. Collaboration advances QLE's laser enrichment technology research and development capabilities.
  • Large US Energy Company (unnamed)coreStrategic or Co-development Partner · 6 March 2026Quantum Leap Energy signed non-binding MOU with major publicly traded US energy company to evaluate support for establishing advanced nuclear fuel production facilities in the US. Facilities would produce HALEU and LEU+ and provide uranium conversion and deconversion services. Addresses US domestic enrichment capacity needs ahead of 2028 Russian uranium import ban.
  • Necsa (South African Nuclear Energy Corporation)coreStrategic or Co-development Partner · 20 February 2026Quantum Leap Energy executed Pre-Implementation Services Contract with Necsa for siting, design, construction, and operation of a HALEU enrichment facility at Necsa's Pelindaba site. Collaboration leverages QLE's proprietary enrichment technology with Necsa's established nuclear infrastructure. Addresses growing global demand for HALEU fuel for small modular reactors.
  • Fermi AmericacoreStrategic or Co-development Partner · 17 February 2026Joint venture with Fermi America (led by former Texas Governor Rick Perry) for development of HALEU enrichment research and commercial production facility in Amarillo, Texas. Partnership part of Project Matador - proposed 18+ million square foot AI campus powered by nuclear reactors. ASP Isotopes securing advanced reactor fuel supply for major US infrastructure project.
  • Skyline Builders Group Holding Limited (SKBL)minorStrategic or Co-development Partner · 29 August 2025Quantum Leap Energy acquired controlling interest in SKBL (NASDAQ: SKBL) - holding 79.14% of voting power. QLE intends to use SKBL to pursue opportunities to acquire assets in the critical materials supply chain to help secure important feedstocks vital to US security.
  • IsotopiaminorStrategic or Co-development Partner · 4 June 2025Partnership with Isotopia for cancer therapy isotope development. ASP Isotopes announced $4 million isotope deal for novel antibody-isotope therapy development.
  • TerraPower LLCcoreStrategic or Co-development Partner · 30 October 2024Entered into term sheet with TerraPower (Bill Gates' nuclear company) for construction of HALEU production facility. TerraPower awarded key contracts to ASP Isotopes and Centrus Energy for HALEU fuel supply for its Natrium reactor project. ASP Isotopes positioned as critical supplier for next-generation nuclear fuel.

Scale indicators17 records

Recent moves6 records

Expansion highlights6 records

ASP Isotopes competitors and assessment

Company assessment

Direct peers

  • Centrus Energy: Centrus Energy is the only other company actively producing HALEU in the United States under contract to the Department of Energy and is a direct competitor for nuclear fuel supply to TerraPower and other advanced reactor developers — both Centrus and ASP Isotopes' Quantum Leap Energy subsidiary are pursuing HALEU/LEU+ production for the same advanced reactor customers.
  • SHINE Technologies: SHINE Technologies is an emerging U.S. fusion-and-medical-isotope company producing medical isotopes (Mo-99, I-131, Lu-177) and investigating fusion-based enrichment, directly overlapping with ASP Isotopes' medical isotope and nuclear materials business across radiopharmaceutical supply.
  • Urenco: Urenco is the world's leading commercial uranium enricher (LEU and stable isotopes) using centrifuge technology, competing head-to-head with ASP Isotopes' Aerodynamic Separation Process for nuclear fuel and stable isotope enrichment contracts globally.
  • NorthStar Medical Radioisotopes: NorthStar Medical is a U.S.-based medical isotope producer focused on Mo-99/Tc-99m and therapeutic radioisotopes, providing direct competition in the same radiopharmaceutical segment ASP Isotopes is targeting via its PET Labs radiopharmacy and Carbon-14/Ytterbium-176 programs.
  • Curium Pharma: Curium Pharma is one of the largest nuclear medicine and radiopharmaceutical manufacturers globally, directly comparable to ASP Isotopes' medical isotope portfolio and its radiopharmacy distribution through PET Labs acquisitions in Florida and South Carolina.

Broad incumbents

  • Cameco: Cameco is a large, established nuclear fuel cycle incumbent spanning uranium mining, conversion, and fuel fabrication; while not directly competing in isotope enrichment, it sets the strategic reference point and competitive benchmark for ASP Isotopes' HALEU and uranium conversion services.
  • Orano: Orano (formerly Areva) is a major French nuclear fuel cycle operator covering uranium mining, conversion, enrichment, and fuel fabrication; its global scale and existing enrichment infrastructure represent the broad incumbent benchmark for ASP Isotopes' emerging HALEU and conversion/deconversion ambitions.
  • Linde plc: Linde is one of the world's largest industrial gas producers, including helium production and supply, and operates radiopharmaceutical distribution; comparable to ASP Isotopes' Renergen Virginia Gas helium output (58,000 cu ft/day at Phase 1) and overlap with medical imaging gas customers.
  • BWX Technologies: BWX Technologies designs and manufactures nuclear components and TRISO fuel for advanced reactors and produces medical radioisotopes, positioning it as a broader nuclear industry incumbent relevant to both ASP Isotopes' HALEU fuel manufacturing plans and its medical isotope business.

Others

  • TerraPower: TerraPower is Bill Gates' advanced reactor developer and a key demand-side partner/off-taker for ASP Isotopes' HALEU via the term sheet for the Natrium reactor; not a competitor, but a strategic customer and counterparty that directly determines the volume and timing of ASP's HALEU ramp.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

ASP Isotopes social profiles

Digital presence

ASP Isotopes financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ASP Isotopes leadership team

Management profile

Number of profiles

Profiles10 records

ASP Isotopes subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

ASP Isotopes funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ASP Isotopes M&A and investment

M&A and investment

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ASP Isotopes

What does ASP Isotopes do?

ASP Isotopes manufactures and supplies enriched stable isotopes for medical, semiconductor, and nuclear energy applications, including Silicon-28, Ytterbium-176, Carbon-14, and Barium-137. The company also produces HALEU (High-Assay Low-Enriched Uranium) nuclear fuel through its Quantum Leap Energy subsidiary and helium and LNG (liquefied natural gas) from the Virginia Gas Project.

Is ASP Isotopes a public or private company?

ASP Isotopes is a public company. It is classified as public and is currently operating.

When was ASP Isotopes founded?

ASP Isotopes was founded in 2022. It employs 101 to 250 people.

Where is ASP Isotopes based?

ASP Isotopes is headquartered in Dallas, United States, in the North America region.

How does ASP Isotopes make money?

Four revenue lines are on record. Isotope Sales - Medical/Radiopharmaceuticals are the primary driver. The others are isotope Sales - Semiconductors, helium and LNG Production and HALEU Nuclear Fuel.

Who are ASP Isotopes's main competitors?

Direct peers on record are Centrus Energy, SHINE Technologies, Urenco, NorthStar Medical Radioisotopes and Curium Pharma. Broad incumbents are Cameco, Orano, Linde plc and BWX Technologies. TerraPower is listed as an others.

Does ASP Isotopes have an API?

No public API is recorded for ASP Isotopes.

What industry is ASP Isotopes in?

ASP Isotopes's product category is Stable Isotope Enrichment. Its primary akta.pro industry code is EUAKACAH, HALEU Production & Supply Chain (Feedstock, Enrichment, Downblending), with a secondary code of EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.). Its NAICS code is 32512.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StASP Isotopes (ASPI) Stock Looks Expensive Despite Its 79% SlideASP Isotopes' stock has fallen 78.7% over the past year despite high-profile nuclear fuel deals. The stock trades at a 7.7x sales multiple, far above the industry average of 1.2x, making it appear overvalued on current revenue. Future valuation may depend on whether the company's sales base justifies the premium.Defense WorldASP Isotopes (ASPI) Expected to Post Quarterly Earnings on ThursdayASP Isotopes is expected to report Q3 2026 earnings on November 12th, with analysts projecting a loss of $0.15 per share and revenue of $5.68 million. The company's stock opened at $1.98, and insiders have sold 245,285 shares over the past 90 days. A conference call is scheduled for November 20th.Simply Wall StWestern Uranium Stocks Gaining Attention As Nuclear Fuel Supply TightensThree uranium mining stocks—ASP Isotopes, Global Atomic, and Australian Rare Earths—are profiled for their exposure to nuclear fuel demand. ASP Isotopes reports US$10.6 million revenue, Global Atomic CA$48 million, and Australian Rare Earths A$0.03 million. The article notes unresolved funding and permitting pressures for each.Simply Wall StASP Isotopes (ASPI) Stock Still Looks Expensive As Shares Fell 78%ASP Isotopes shares fell 77.5% over the past year, and the stock trades at an 8.5x price-to-sales ratio, well above the chemicals industry average of 1.2x and peers at 0.7x. A fair-value model suggests the shares are overvalued, and investors must assess whether the company can deliver durable revenue from its isotope and helium opportunities to justify the premium.moneyweekukThe nuclear industry is set to melt up – here’s what to buyNuclear industry stocks have fallen sharply, with some firms trading below cash on their balance sheets. The author argues that inelastic demand and cheap intelligence will drive power consumption up, making nuclear assets undervalued. He recommends buying Lightbridge, ASP Isotopes, and Fermi America.MarketBeatASP Isotopes Targets $300M EBITDA as Helium, Silicon-28 and Radiopharmacy Plans AdvanceASP Isotopes CEO Paul Mann outlined plans to expand its isotope-enrichment, radiopharmacy, and helium businesses, targeting over $300 million in EBITDA by 2031. The company has three manufacturing plants in South Africa for carbon-14, silicon-28, and ytterbium-176, with helium production starting and silicon-28 shipments expected by year-end. It also plans to spin out its nuclear-fuels business and list its helium asset on Nasdaq.BusinessLIVEASP Isotopes’ Renergen achieves stable helium output at Virginia projectASP Isotopes' Renergen achieved stable liquid helium production at the Virginia project in the Free State, storing output ahead of initial deliveries. The company expects phase 1 to reach planned capacity by year-end, with initial deliveries not yet begun. Phase 2, about 13 times larger, has secured up to $750m in senior debt.MarketWatchASP Isotopes Shares Rise After Gas Project Achieves Stable Liquid Helium ProductionASP Isotopes shares rose after its subsidiary Tetra4 completed commissioning and achieved stable liquid helium production. The stock was 4% higher at $2.03, though down 79% over the past year. The Virginia Gas Project is South Africa's first integrated producer of liquid helium and LNG, with Phase 1 expected to produce 2,500 gigajoules per day of LNG and 70,000 cubic feet per day of helium.Journal quotidien La TribuneNucléaire civil : l’Afrique du Sud s'intéresse à nouveau à l’enrichissement d’uraniumASP Isotopes signed a framework agreement with South Africa's Necsa to build a uranium enrichment plant at Pelindaba, with Quantum Leap Energy holding 80% of the joint venture. The plant will produce HALEU for advanced reactors, with a potential client TerraPower already committed. Production is expected to begin in 2027.Ticker ReportASP Isotopes (NASDAQ:ASPI) versus Mativ (NYSE:MATV) Head-To-Head AnalysisASP Isotopes and Mativ are compared on financials, ownership, and analyst ratings. ASP Isotopes has lower revenue but higher earnings per share and a lower P/E ratio, while Mativ has higher revenue and profitability. Analysts rate ASP Isotopes more favorably with a higher consensus target price.